MCID: LMB062
MIFTS: 54

Limb Ischemia

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Limb Ischemia

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia 11 14 36 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0050852
UMLS 71 C2945695

Summaries for Limb Ischemia

Disease Ontology: 11 An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary: Limb Ischemia is related to intermittent claudication and temporal arteritis. An important gene associated with Limb Ischemia is MIR126 (MicroRNA 126), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Acetylsalicylic acid and Evolocumab have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are nervous system and homeostasis/metabolism

Related Diseases for Limb Ischemia

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 intermittent claudication 32.0 VWF VEGFA TEK IL6 CRP
2 temporal arteritis 31.9 VWF VEGFA IL6 CRP
3 ischemia 31.4 VEGFA TEK NOS3 MIR21 MIR17 MIR126
4 peripheral vascular disease 31.4 VWF VEGFA NOS3 MIR126 KDR IL6
5 compartment syndrome 31.3 IL6 F3 CRP
6 peripheral artery disease 31.3 VWF VEGFA PECAM1 NOS3 MIR21 MIR17
7 arteriosclerosis obliterans 31.3 MIR21 MIR126 IL6 HGF
8 buerger disease 31.2 VEGFA NOS3 HGF FGF2 CRP CD34
9 aortic dissection 31.2 NOS3 IL6 HIF1A CRP
10 congestive heart failure 31.1 VWF VEGFA IL6 ANGPT1
11 adult respiratory distress syndrome 31.0 MIR21 MIR126 IL6 CRP ANGPT1
12 cerebrovascular disease 31.0 MIR21 MIR17 MIR126 IL6 CRP
13 covid-19 30.9 NOS3 IL6 F3 CRP
14 arteries, anomalies of 30.9 VEGFA NOS3 MIR21 MIR17 MIR126 MIR10A
15 aortic aneurysm 30.9 VEGFA NOS3 MIR21 MIR126 IL6 F3
16 chronic kidney disease 30.8 VWF NOS3 MIR21 MIR126 IL6 HGF
17 systemic scleroderma 30.7 VEGFA MIR21 IL6 CRP CD34
18 aortic aneurysm, familial abdominal, 1 30.7 VEGFA PECAM1 NOS3 MIR21 MIR126 IL6
19 lipid metabolism disorder 30.7 NOS3 MIR21 MIR17 MIR126 IL6 CRP
20 collagen disease 30.6 VWF IL6 CRP
21 polyarteritis nodosa 30.6 PECAM1 IL6 CRP
22 toxic shock syndrome 30.6 IL6 F3 CRP
23 pulmonary embolism 30.6 VWF MIR126 F3 CRP
24 heart septal defect 30.6 MIR17 F3 CRP
25 antiphospholipid syndrome 30.6 VWF F3 CRP
26 atherosclerosis susceptibility 30.6 VWF NOS3 IL6 F3 CRP
27 patent foramen ovale 30.6 VWF IL6 F3 CRP
28 arteriosclerosis 30.5 PECAM1 MIR21 MIR126 IL6 HIF1A HGF
29 essential thrombocythemia 30.5 VWF IL6 FGF2 CD34
30 severe covid-19 30.5 VWF MIR21 IL6 F3 CRP
31 pulmonary edema 30.5 TEK NOS3 HIF1A HGF CRP
32 urinary tract infection 30.5 IL6 F3 CRP
33 microvascular complications of diabetes 1 30.5 VEGFA HIF1A HGF FGF2 CXCL12 ANGPT1
34 vascular disease 30.5 VWF VEGFA TEK NOS3 MIR21 MIR126
35 respiratory failure 30.4 VWF VEGFA MIR21 MIR17 MIR126 IL6
36 transient cerebral ischemia 30.4 VWF IL6 F3 CRP
37 disseminated intravascular coagulation 30.4 VWF IL6 F3 CRP
38 thrombocytosis 30.4 VWF IL6 F3 CRP
39 leukostasis 30.4 VEGFA KDR IL6
40 nonbacterial thrombotic endocarditis 30.4 VWF F3 CRP
41 angina pectoris 30.4 NOS3 IL6 F3 CRP
42 chronic ulcer of skin 30.3 VEGFA MIR21 IL6 FGF2 CRP
43 atrial fibrillation 30.3 VWF MIR21 IL6 F3 CRP
44 purpura 30.3 VWF IL6 F3 CRP
45 necrotizing fasciitis 30.3 IL6 F3 CRP
46 hyperglycemia 30.3 NOS3 MIR126 IL6 HIF1A
47 varicose veins 30.3 VWF VEGFA KDR IL6 HIF1A
48 cellulitis 30.3 IL6 F3 CRP
49 aortic valve disease 2 30.3 VWF MIR21 MIR17 MIR126 CRP
50 polycythemia 30.3 VEGFA HIF1A F3 CRP

Graphical network of the top 20 diseases related to Limb Ischemia:



Diseases related to Limb Ischemia

Symptoms & Phenotypes for Limb Ischemia

MGI Mouse Phenotypes related to Limb Ischemia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.31 ANGPT1 CXCL12 ENG F3 FGF2 HGF
2 homeostasis/metabolism MP:0005376 10.31 ANGPT1 CD34 CRP ENG F3 FGF2
3 cardiovascular system MP:0005385 10.27 ANGPT1 CRP CXCL12 ENG F3 FGF2
4 muscle MP:0005369 10.26 ANGPT1 CXCL12 ENG F3 FGF2 HIF1A
5 cellular MP:0005384 10.22 CD34 CXCL12 F3 FGF2 HGF HIF1A
6 normal MP:0002873 10.18 CXCL12 ENG F3 HIF1A KDR MIR10A
7 immune system MP:0005387 10.13 ANGPT1 CD34 CRP CXCL12 ENG F3
8 neoplasm MP:0002006 10.08 CD34 F3 FGF2 HIF1A IL6 MIR10A
9 liver/biliary system MP:0005370 10.06 CXCL12 HGF HIF1A IL6 KDR NOS3
10 no phenotypic analysis MP:0003012 10.05 CXCL12 HGF KDR MIR10A MIR126 VEGFA
11 respiratory system MP:0005388 9.91 ENG F3 HIF1A IL6 KDR MIR126
12 vision/eye MP:0005391 9.85 ANGPT1 F3 FGF2 HIF1A IL6 KDR
13 hematopoietic system MP:0005397 9.83 CD34 CXCL12 ENG F3 FGF2 HGF
14 mortality/aging MP:0010768 9.5 ANGPT1 CXCL12 ENG F3 FGF2 HGF

Drugs & Therapeutics for Limb Ischemia

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
2
Evolocumab Approved Phase 4 1256937-27-5
3
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
6
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
7
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
8 Anti-Asthmatic Agents Phase 4
9 Respiratory System Agents Phase 4
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
11 Antimetabolites Phase 4
12 Hypolipidemic Agents Phase 4
13 Anticholesteremic Agents Phase 4
14 Lipid Regulating Agents Phase 4
15 Fibrinolytic Agents Phase 4
16 Antipyretics Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Bronchodilator Agents Phase 4
19 Neuroprotective Agents Phase 4
20 Phosphodiesterase Inhibitors Phase 4
21 Phosphodiesterase 3 Inhibitors Phase 4
22 Pharmaceutical Solutions Phase 4
23 Vasodilator Agents Phase 4
24 Hormone Antagonists Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Antiemetics Phase 4
27 glucocorticoids Phase 4
28 Gastrointestinal Agents Phase 4
29 Hormones Phase 4
30 Analgesics Phase 4
31 Calcium, Dietary Phase 4
32 Anti-Anxiety Agents Phase 4
33 Psychotropic Drugs Phase 4
34 Anticonvulsants Phase 4
35 calcium channel blockers Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
Caffeine Approved Phase 3 58-08-2 2519
38
Apixaban Approved Phase 3 503612-47-3 10182969
39
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
40
Iron Approved Phase 3 7439-89-6 29936
41
Pentetic acid Approved Phase 3 67-43-6
42
Procaine Approved, Investigational, Vet_approved Phase 3 59-46-1 4914
43
Montelukast Approved Phase 3 158966-92-8 5281040
44
Iodine Approved, Investigational Phase 3 7553-56-2 807
45
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
46
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
47
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
48
Clopidogrel Approved Phase 2, Phase 3 120202-66-6, 113665-84-2 60606
49
Ticagrelor Approved Phase 2, Phase 3 274693-27-5 9871419
50
Treprostinil Approved, Investigational Phase 3 81846-19-7 6918140

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 Effect of Evolocumab in Patients With Critical Limb Ischemia Unknown status NCT04306471 Phase 4 Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
2 Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia. Unknown status NCT04312555 Phase 4 Alprostadil
3 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Unknown status NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
4 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
5 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
6 Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans Completed NCT02117206 Phase 4 L-arginine (L-arginine Veyron);Nacl
7 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
8 CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5). Completed NCT00459888 Phase 4
9 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
10 International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease Completed NCT02369809 Phase 4 Neovasculgen®
11 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
12 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex). Completed NCT00300690 Phase 4
13 Randomized Controlled Trial of Paclitaxel Drug-coated Balloons vs. Nitinol Stent for Femoropopliteal Obstructions - The PAVENST Trial Completed NCT02212470 Phase 4
14 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study Completed NCT01558505 Phase 4
15 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Completed NCT02563535 Phase 4
16 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
17 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Active, not recruiting NCT02807779 Phase 4 Dexamethasone infusion
18 Physician-initiated Trial Investigating the MOTIV™ Bioresorbable Scaffold (Reva Medical) for the Treatment of Below-The-Knee Artery Disease Active, not recruiting NCT03987061 Phase 4
19 Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study Terminated NCT00403780 Phase 4 pregabalin;placebo
20 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
21 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Withdrawn NCT02408991 Phase 4 Neupogen
22 Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Unknown status NCT03006770 Phase 3
23 Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients Unknown status NCT02538978 Phase 3
24 An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia Unknown status NCT02856230 Phase 2, Phase 3
25 Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
26 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
27 Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia Unknown status NCT02820467 Phase 3
28 Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
29 Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells Completed NCT02454231 Phase 2, Phase 3
30 Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease Completed NCT01245335 Phase 3
31 Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG) Completed NCT01818310 Phase 2, Phase 3
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization Completed NCT01483898 Phase 3
33 Cell Therapy in Critical Limb Ischemia Completed NCT00904501 Phase 3
34 A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions Completed NCT00566657 Phase 3
35 Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb Recruiting NCT04229264 Phase 3 Apixaban;ASA;Clopidogrel 75mg
36 Trial to Assess Chelation Therapy in Critical Limb Ischemia Recruiting NCT03982693 Phase 3 Edetate Disodium
37 Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study Recruiting NCT01450722 Phase 3
38 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 5) Recruiting NCT04274049 Phase 3
39 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4) Recruiting NCT04275323 Phase 3
40 Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI) Active, not recruiting NCT03423732 Phase 2, Phase 3 CardioCell;Placebos
41 A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia Active, not recruiting NCT03551496 Phase 3
42 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Active, not recruiting NCT03174522 Phase 3 REX-001;Placebo
43 Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia Active, not recruiting NCT00471289 Phase 2, Phase 3
44 The Assessment of Cysteinyl Leukotriene Receptor Antagonist Role in Inhibition of Atherosclerosis, Proliferation and Its Influence on Endothelial Function in Patients Undergoing Endovascular Treatment Due to Peripheral Arterial Disease. Not yet recruiting NCT04277702 Phase 3 Montelukast 10mg;Standard anti-platelet treatment
45 Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients With Symptomatic Rutherford 3-5 Peripheral Artery Disease Not yet recruiting NCT04433572 Phase 3 Temsirolimus;Saline placebo
46 Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery Not yet recruiting NCT05372718 Phase 3 Recombinant non-immunogenic staphylokinase (Fortelyzin®)
47 A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia Terminated NCT02144610 Phase 3
48 A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures Terminated NCT00060996 Phase 3 Remodulin® (treprostinil sodium) Injection
49 Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase Terminated NCT01638585 Phase 3 urokinase
50 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Terminated NCT03111238 Phase 3 REX-001;Placebo

Search NIH Clinical Center for Limb Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Limb Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Limb Ischemia:
ACP-01, autologous angiogenic precursor cells for critical limb ischemia
ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
Autologous CD133+ cells for treatment of critical limb ischemia
Autologous endothelial progenitor cells for the treatment of critical limb ischemia
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for critical limb ischemia
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
Bone marrow-derived stem cells for treatment of diabetic foot ulcers
Enriched bone marrow-derived progenitor cells for ischemic diseases
ERCs, endometrial regenerative cells for critical limb ischemia
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
Mesendo, stem cell combination for treatment of limb ischemia
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
PDA002, Placenta-derived cells for vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
ReN009, human neural stem cells for peripheral arterial disease
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
StempeucelCLI, mesenchymal stem cells for vascular diseases
Umbilical cord blood stem cells for treatment of critical limb ischemia
Embryonic/Adult Cultured Cells Related to Limb Ischemia:
Angiogenic cell precursors
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 9020076 23192920 22163120
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Bone marrow-derived mononuclear cells (family) PMIDs: 17394441 23586040 21216483
Peripheral blood-derived endothelial progenitor cells (family)
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 18351022 22019148 19896796 19500466
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Tissue repair cells PMIDs: 17394441 23586040
Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
Bone marrow-derived progenitor cells
Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
Bone marrow-derived mononuclear cells PMIDs: 21586448
MultiGeneAngio, transduced vein-derived endothelial cells
Genetically modified vein-derived smooth muscle
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived endothelial cells
Placenta-derived cells
Peripheral blood-derived hematopoietic stem cells
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
Neural stem cell line (CTX0E03) PMIDs: 23067568
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 23307180 18720444 22731756
Umbilical cord blood-derived hematopoietic stem cells (family)

Genetic Tests for Limb Ischemia

Anatomical Context for Limb Ischemia

Organs/tissues related to Limb Ischemia:

MalaCards : Bone Marrow, Bone, Placenta, Endothelial, Smooth Muscle, Skeletal Muscle, Small Intestine
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Limb Ischemia:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
3 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Limb Ischemia

Articles related to Limb Ischemia:

(show top 50) (show all 8740)
# Title Authors PMID Year
1
Study Protocol of a Prospective Multicenter Observational Study Evaluating Acute Lower Limb Ischemia. 62
36347128 2023
2
Acute limb ischaemia in a young male with secondary polycythaemia: A case report. 62
36452889 2023
3
Free floating aorto-iliac thrombosis: A rare complication of COVID-19 pneumonia. 62
36415471 2023
4
Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for Cardiogenic Shock: A Systematic Review and Meta-analysis. 62
36174742 2023
5
Development of a Non-Invasive Local Heating Load Test to Detect Severe Limb Ischemia Within 200 seconds. 62
35968758 2023
6
New experimental model of hind limb ischemia in pot-bellied pigs. 62
36089076 2023
7
Frailty predicts poor longer-term outcomes in patients following lower limb open surgical revascularization. 62
36168946 2022
8
Temporal analysis of skeletal muscle remodeling post hindlimb ischemia reveals intricate autophagy regulation. 62
36252128 2022
9
Unexpected arterial thrombosis and acute limb ischemia in COVID-19 patients. Results from the Ibero-Latin American acute arterial thrombosis registry in COVID-19: (ARTICO-19). 62
34866506 2022
10
Comparative study of mouse adipose- and bone marrow mesenchymal stem cells in diabetic model with critical limb ischemia. 62
35590084 2022
11
Arterial thoracic outlet syndrome: a 30-year experience in a high-volume referral center. 62
36106396 2022
12
Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Bypass Surgery with Venous and Prosthetic Conduits. 62
36470531 2022
13
Endothelium dysfunction in hind limb arteries of male Zucker Diabetic-Sprague Dawley rats. 62
36279920 2022
14
Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries. 62
34905961 2022
15
Prevalence of frailty in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. 62
36216291 2022
16
Resuscitating the resuscitation: A single-centre experience on extracorporeal cardiopulmonary resuscitation. 62
36453833 2022
17
Novel approaches to antiplatelet therapy. 62
36243098 2022
18
Cannulation-related adverse events of peripheral veno-arterial extracorporeal membrane oxygenation support in heart transplantation: Axillary versus femoral artery cannulation. 62
36468757 2022
19
A remarkably rare case of Adventitial Cystic Disease of the Popliteal Artery in a 51-year-old Middle Eastern female - A Case Report. 62
36462233 2022
20
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study. 62
36461057 2022
21
Buttock Ischemia in Venoarterial Extracorporeal Membrane Oxygenation: A Case Series. 62
35275880 2022
22
Prolonged lower extremity endovascular procedures for patients with claudication increase risk of adverse outcomes. 62
35840074 2022
23
Association of Clinical Setting With Sociodemographics and Outcomes Following Endovascular Femoropopliteal Artery Revascularization in the United States. 62
36472193 2022
24
Saphenous and sciatic nerve block to treat acute lower limb ischemic pain in the emergency department. 62
35460505 2022
25
Long-term Follow-up of a Randomized Clinical Trial Comparing Endovascular Revascularization Plus Supervised Exercise With Supervised Exercise Only for Intermittent Claudication. 62
33378308 2022
26
2D perfusion angiography: an alternative method to evaluate endovascular intervention for acute lower limb ischemia. 62
36463099 2022
27
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial. 62
35999133 2022
28
Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases. 62
36370875 2022
29
Cryptogenic acute lower extremities and multiorgan ischemia in an 8-year-old girl. 62
36248384 2022
30
Ten-year experience of infrainguinal bypass with endoscopic vein harvest. 62
36446034 2022
31
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs without left ventricular unloading by Impella: a systematic review and meta-analysis. 62
36370449 2022
32
Access site complications of postcardiotomy extracorporeal life support. 62
34949456 2022
33
Midterm Outcomes of Endovascular Versus Open Surgical Repair of Intact Descending Thoracic Aneurysms in Patients with Connective Tissue Disorders. 62
35460854 2022
34
Denser fibrin clot networks in patients at high risk of recurrent arterial thromboembolism following acute limb ischemia of unknown cause. 62
36264044 2022
35
Comparisons of outcomes of open surgery versus endovascular intervention for thrombotic popliteal artery aneurysm with acute lower limb ischemia: a systematic review. 62
36401240 2022
36
AhR regulates VEGF expression by promoting STAT1 transcriptional activity, thereby affecting endothelial angiogenesis in acute limb ischemia. 62
36347318 2022
37
Adipose-derived stem cell-secreted exosomes enhance angiogenesis by promoting macrophage M2 polarization in type 2 diabetic mice with limb ischemia via the JAK/STAT6 pathway. 62
36406687 2022
38
Large thrombus in non-atherosclerotic thoracic ascending aorta as the source of acute upper limb ischemia in a young cocaine user. 62
36441134 2022
39
Peripherally inserted concomitant surgical right and left ventricular support, the Propella, is associated with low rates of limb ischemia, with mortality comparable with peripheral venoarterial extracorporeal membrane oxygenation. 62
36435648 2022
40
Characteristics and Outcomes of Patients Transferred for Treatment of Acute Limb Ischemia. 62
35803462 2022
41
Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial. 62
35802311 2022
42
Radio-iodination and biological evaluation of pentoxifylline as a novel probe for diagnosis of intermittent claudication. 62
36037727 2022
43
Catastrophic Vascular Injury After Total Knee Arthroplasty. 62
36098573 2022
44
Acute Limb Arterial Ischemia Following Iliac Vein Stenting in the Setting of a Frozen Pelvis. 62
35921088 2022
45
Effects of sensory nerve blockade on cutaneous microvascular responses to ischemia-reperfusion injury. 62
35970407 2022
46
Randomized Trials of Percutaneous Microaxial Flow Pump Devices: JACC State-of-the-Art Review. 62
36396205 2022
47
Differences in major limb outcomes by indication for lower extremity endovascular revascularization in patients receiving hemodialysis. 62
36322238 2022
48
CircANKRD12 Is Induced in Endothelial Cell Response to Oxidative Stress. 62
36428974 2022
49
Chronic Anti-Coagulation Therapy Reduced Mortality In Patients With High Cardiovascular Risk Early In COVID-19 Pandemic. 62
36415466 2022
50
COVID-19 related peripheral arterial thrombotic events in intensive care unit and non-intensive care unit patients: A retrospective case series. 62
36395575 2022

Variations for Limb Ischemia

Expression for Limb Ischemia

Search GEO for disease gene expression data for Limb Ischemia.

Pathways for Limb Ischemia

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 VEGFA TEK KDR IL6 HIF1A HGF
2 13.67 ANGPT1 CXCL12 F3 FGF2 HGF HIF1A
3
Show member pathways
13.62 VEGFA TEK NOS3 KDR IL6 HGF
4
Show member pathways
13.55 CRP CXCL12 FGF2 HGF IL6 KDR
5
Show member pathways
13.53 VEGFA TEK KDR IL6 HGF FGF2
6
Show member pathways
13.37 VWF TEK KDR IL6 HGF FGF2
7
Show member pathways
13.35 ANGPT1 CXCL12 FGF2 HGF IL6 KDR
8
Show member pathways
13.28 TEK KDR IL6 HGF FGF2 CXCL12
9
Show member pathways
13.23 VWF VEGFA TEK PECAM1 NOS3 HGF
10
Show member pathways
13.21 CXCL12 FGF2 HGF IL6 KDR NOS3
11
Show member pathways
13.04 KDR IL6 HIF1A HGF FGF2 CXCL12
12
Show member pathways
12.83 ANGPT1 FGF2 HGF HIF1A IL6 KDR
13 12.69 VEGFA NOS3 KDR HIF1A HGF FGF2
14
Show member pathways
12.68 KDR IL6 HGF FGF2 CXCL12
15
Show member pathways
12.55 TEK NOS3 IL6 FGF2 ANGPT1
16 12.52 VEGFA TEK KDR IL6 HIF1A HGF
17
Show member pathways
12.35 TEK KDR IL6 HGF FGF2 CXCL12
18 12.27 HGF KDR VEGFA VWF
19
Show member pathways
12.18 VEGFA NOS3 KDR FGF2
20 12.02 VEGFA KDR IL6 HGF FGF2
21 11.89 VEGFA IL6 HIF1A HGF FGF2
22 11.85 IL6 FGF2 ENG CD34
23 11.82 VEGFA KDR HIF1A
24
Show member pathways
11.77 IL6 HIF1A CRP
25 11.73 IL6 CXCL12 CRP
26 11.68 VEGFA PECAM1 IL6 HGF CXCL12
27 11.66 VEGFA NOS3 KDR
28 11.66 IL6 HGF FGF2
29 11.66 VEGFA HIF1A ENG CXCL12
30 11.65 MIR21 MIR126 IL6
31 11.6 VEGFA KDR FGF2
32 11.57 VEGFA IL6 HIF1A
33 11.56 VEGFA NOS3 HIF1A
34 11.55 VEGFA PECAM1 KDR HGF
35 11.51 VEGFA KDR FGF2
36 11.49 VEGFA IL6 HGF FGF2
37
Show member pathways
11.47 VEGFA KDR HGF
38 11.45 VEGFA KDR CXCL12
39 11.44 VEGFA KDR FGF2
40 11.38 VEGFA PECAM1 KDR
41 11.36 VEGFA HIF1A ANGPT1
42 11.27 KDR HIF1A CXCL12 ANGPT1
43 11.27 VWF TEK PECAM1 NOS3 KDR HIF1A
44
Show member pathways
11.25 VEGFA HIF1A CRP
45 11.17 VEGFA NOS3 HIF1A
46 11.17 VEGFA TEK NOS3 KDR IL6 ANGPT1
47 10.98 TEK KDR IL6 HGF FGF2 CXCL12
48 10.83 TEK NOS3 KDR HIF1A FGF2
49 10.71 VEGFA NOS3
50
Show member pathways
10.66 VEGFA HIF1A

GO Terms for Limb Ischemia

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 VWF VEGFA TEK KDR IL6 HGF
2 extracellular space GO:0005615 9.72 ANGPT1 CRP CXCL12 ENG F3 FGF2

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.44 ANGPT1 HGF HIF1A IL6 KDR MIR21
2 negative regulation of gene expression GO:0010629 10.37 VEGFA MIR21 MIR17 KDR HIF1A FGF2
3 angiogenesis GO:0001525 10.34 VEGFA TEK NOS3 KDR HIF1A FGF2
4 positive regulation of cell migration GO:0030335 10.32 CXCL12 F3 HGF KDR MIR10A MIR21
5 positive regulation of protein phosphorylation GO:0001934 10.3 ANGPT1 ENG FGF2 HGF KDR MIR21
6 positive regulation of gene expression GO:0010628 10.3 ANGPT1 CD34 CRP ENG F3 FGF2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.29 VEGFA TEK MIR21 MIR126 KDR FGF2
8 positive regulation of MAPK cascade GO:0043410 10.29 FGF2 HGF IL6 KDR MIR126 TEK
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.28 ANGPT1 HGF IL6 PECAM1 VEGFA
10 positive regulation of endothelial cell proliferation GO:0001938 10.25 VEGFA TEK KDR HIF1A FGF2 F3
11 positive chemotaxis GO:0050918 10.21 VEGFA HGF FGF2 ANGPT1
12 lung development GO:0030324 10.19 FGF2 KDR NOS3 VEGFA
13 positive regulation of interleukin-10 production GO:0032733 10.18 IL6 HGF CD34
14 positive regulation of osteoblast differentiation GO:0045669 10.17 MIR21 IL6 HGF FGF2
15 positive regulation of endothelial cell migration GO:0010595 10.17 ANGPT1 FGF2 KDR MIR21 TEK VEGFA
16 cellular response to hypoxia GO:0071456 10.16 VEGFA MIR17 MIR126 HIF1A
17 branching involved in blood vessel morphogenesis GO:0001569 10.14 VEGFA KDR ENG
18 positive regulation of neuroblast proliferation GO:0002052 10.13 VEGFA HIF1A FGF2
19 positive regulation of protein kinase B signaling GO:0051897 10.13 VEGFA TEK MIR21 MIR126 FGF2 F3
20 positive regulation of focal adhesion assembly GO:0051894 10.12 VEGFA TEK KDR
21 endothelial cell proliferation GO:0001935 10.12 TEK FGF2 CD34
22 sprouting angiogenesis GO:0002040 10.12 ANGPT1 ENG TEK VEGFA
23 negative regulation of endothelial cell apoptotic process GO:2000352 10.11 ANGPT1 KDR MIR126 TEK
24 cell migration involved in sprouting angiogenesis GO:0002042 10.1 VEGFA KDR FGF2
25 positive regulation of positive chemotaxis GO:0050927 10.09 F3 KDR VEGFA
26 vascular wound healing GO:0061042 10.08 VEGFA KDR CD34
27 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 10.06 VEGFA MIR126 MIR10A KDR FGF2
28 positive regulation of sprouting angiogenesis GO:1903672 10.04 VEGFA MIR126 FGF2
29 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.03 MIR21 MIR17 IL6 HIF1A
30 positive regulation of DNA biosynthetic process GO:2000573 10.02 VEGFA HGF FGF2
31 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10 MIR21 MIR17 FGF2
32 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 10 KDR VEGFA
33 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.99 KDR VEGFA
34 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.99 HIF1A VEGFA
35 Tie signaling pathway GO:0048014 9.98 ANGPT1 TEK
36 glomerular endothelium development GO:0072011 9.97 CD34 PECAM1
37 glomerulus vasculature development GO:0072012 9.97 ANGPT1 TEK
38 positive regulation of blood vessel endothelial cell migration GO:0043536 9.97 ANGPT1 FGF2 HIF1A KDR MIR126 NOS3
39 positive regulation of vascular endothelial cell proliferation GO:1905564 9.93 FGF2 MIR126 MIR21
40 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.93 MIR10A MIR126 MIR21 VEGFA
41 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.88 MIR21 IL6
42 positive regulation of epithelial tube formation GO:1905278 9.86 VEGFA FGF2
43 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.84 HGF MIR21
44 positive regulation of vascular associated smooth muscle cell differentiation GO:1905065 9.83 MIR21 ENG
45 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 VEGFA TEK MIR21 MIR126 KDR HGF
46 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.69 MIR17 MIR21
47 positive regulation of metalloendopeptidase activity GO:1904685 9.68 MIR21 MIR17
48 positive regulation of angiogenesis GO:0045766 9.66 CD34 ENG F3 FGF2 HGF HIF1A

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.46 MIR21 MIR17 MIR126 MIR10A
2 chemoattractant activity GO:0042056 9.43 VEGFA HGF FGF2
3 growth factor activity GO:0008083 9.32 VEGFA IL6 HGF FGF2 CXCL12

Sources for Limb Ischemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....